tetano
Editor, Senior Moderator
J Cyst Fibros. 2020 Apr 25. pii: S1569-1993(20)30125-9. doi: 10.1016/j.jcf.2020.04.012. [Epub ahead of print]
A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis.
Cosgriff R[SUP]1[/SUP], Ahern S[SUP]2[/SUP], Bell SC[SUP]3[/SUP], Brownlee K[SUP]4[/SUP], Burgel PR[SUP]5[/SUP], Byrnes C[SUP]6[/SUP], Corvol H[SUP]7[/SUP], Cheng SY[SUP]8[/SUP], Elbert A[SUP]9[/SUP], Faro A[SUP]9[/SUP], Goss CH[SUP]10[/SUP], Gulmans V[SUP]11[/SUP], Marshall BC[SUP]9[/SUP], McKone E[SUP]12[/SUP], Middleton PG[SUP]13[/SUP], Ruseckaite R[SUP]2[/SUP], Stephenson AL[SUP]14[/SUP], Carr SB[SUP]15[/SUP].
Author information
Abstract
Information is lacking on the clinical impact of the novel coronavirus, SARS-CoV-2, on people with cystic fibrosis (CF). Our aim was to characterise SARS-CoV-2 infection in people with cystic fibrosis.
METHODS:
Anonymised data submitted by each participating country to their National CF Registry was reported using a standardised template, then collated and summarised.
RESULTS:
40 cases have been reported across 8 countries. Of the 40 cases, 31 (78%) were symptomatic for SARS-CoV-2 at presentation, with 24 (60%) having a fever. 70% have recovered, 30% remain unresolved at time of reporting, and no deaths have been submitted.
CONCLUSIONS:
This early report shows good recovery from SARS-CoV-2 in this heterogeneous CF cohort. The disease course does not seem to differ from the general population, but the current numbers are too small to draw firm conclusions and people with CF should continue to strictly follow public health advice to protect themselves from infection.
Copyright ? 2020. Published by Elsevier B.V.
KEYWORDS:
Coronavirus; Cystic fibrosis; SARS-CoV-2
PMID:32376098DOI:10.1016/j.jcf.2020.04.012
A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis.
Cosgriff R[SUP]1[/SUP], Ahern S[SUP]2[/SUP], Bell SC[SUP]3[/SUP], Brownlee K[SUP]4[/SUP], Burgel PR[SUP]5[/SUP], Byrnes C[SUP]6[/SUP], Corvol H[SUP]7[/SUP], Cheng SY[SUP]8[/SUP], Elbert A[SUP]9[/SUP], Faro A[SUP]9[/SUP], Goss CH[SUP]10[/SUP], Gulmans V[SUP]11[/SUP], Marshall BC[SUP]9[/SUP], McKone E[SUP]12[/SUP], Middleton PG[SUP]13[/SUP], Ruseckaite R[SUP]2[/SUP], Stephenson AL[SUP]14[/SUP], Carr SB[SUP]15[/SUP].
Author information
Abstract
Information is lacking on the clinical impact of the novel coronavirus, SARS-CoV-2, on people with cystic fibrosis (CF). Our aim was to characterise SARS-CoV-2 infection in people with cystic fibrosis.
METHODS:
Anonymised data submitted by each participating country to their National CF Registry was reported using a standardised template, then collated and summarised.
RESULTS:
40 cases have been reported across 8 countries. Of the 40 cases, 31 (78%) were symptomatic for SARS-CoV-2 at presentation, with 24 (60%) having a fever. 70% have recovered, 30% remain unresolved at time of reporting, and no deaths have been submitted.
CONCLUSIONS:
This early report shows good recovery from SARS-CoV-2 in this heterogeneous CF cohort. The disease course does not seem to differ from the general population, but the current numbers are too small to draw firm conclusions and people with CF should continue to strictly follow public health advice to protect themselves from infection.
Copyright ? 2020. Published by Elsevier B.V.
KEYWORDS:
Coronavirus; Cystic fibrosis; SARS-CoV-2
PMID:32376098DOI:10.1016/j.jcf.2020.04.012